This week, Indivior Inc. agreed to pay $10 million to settle Federal Trade Commission charges that it had violated antitrust laws through a deceptive scheme to stop lower-priced generic competition with its opioid replacement therapy drug Suboxone. The purposed stipulated order bars Indivior from engaging in similar behavior in the future. Suboxone is used to… Continue reading Indivior Inc To Pay $10 Million After Settling FTC Charges It Used Anticompetitive Tactics To Impede Competition From Lower-Cost Suboxone Generics